Home  /  Resource Library  /  Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low Tumor Burden Follicular Lymphoma: Results of a LYSA Study

Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low Tumor Burden Follicular Lymphoma: Results of a LYSA Study

Results of a study investigating subcutaneous rituximab in front line treatment for follicular lymphoma. (Abstract only)